Understanding Your Diagnosis (ALS24 / NEK1)
At a Glance
ALS24 is ALS linked with a change in the NEK1 gene. A NEK1 change usually raises risk rather than guaranteeing disease, and current evidence suggests its course is generally similar to ALS without a known genetic cause. Care is based on symptoms, progression, breathing, and team support.
An ALS diagnosis is a profound and life-altering event. When that diagnosis is accompanied by the news that a specific genetic variant has been found, it can add a new layer of complexity and emotional weight. It is natural to feel overwhelmed or to wonder what this means for your future and your family. Understanding the specifics of ALS24—the term used for ALS associated with the NEK1 gene—can help you navigate these conversations with your medical team.
What is ALS24?
ALS24 is a form of amyotrophic lateral sclerosis (ALS) that is associated with a specific change (a variant) in the NEK1 gene [1]. This gene provides instructions for making a protein that helps maintain the structure of your motor neurons and helps the cells repair their DNA [2][3]. When the NEK1 protein doesn’t function correctly, it can lead to the cellular stress and damage seen in ALS [4].
While the genetic label is specific, it is important to know that ALS24 is not a different “disease” than ALS, nor does a gene result alone diagnose the disease. In most clinical ways, it looks and behaves very much like other forms of ALS [5].
Risk vs. Certainty: Understanding Your Results
Genetic findings in ALS are often divided into different categories based on risk.
- Highly Penetrant genes (like some variants in the SOD1 gene) carry a very high, age-dependent risk of disease, though they do not guarantee symptoms by a particular age.
- Susceptibility (risk) genes like NEK1 are different. Carrying a NEK1 variant increases your risk of developing ALS, but it does not make the disease inevitable [1][6].
This concept is known as incomplete penetrance [7]. Research has found that some people carry NEK1 variants their entire lives and never develop symptoms of ALS [8][9]. Scientists hypothesize that for someone with a NEK1 variant to develop ALS, other factors—such as their environment, other genes, or the natural aging process—may also contribute [10]. In many cases, a NEK1 variant is viewed as one “hit” in a series of events that eventually leads to the disease [11].
How to Read Your Genetic Result
When looking at your laboratory report with your doctor or genetic counselor, pay attention to these key details:
- The Gene and Variant Notation: Look for the specific code (e.g., NEK1 c.2434A>G). This exact code is what other doctors need to understand your result.
- Laboratory Classification: Is it marked as Pathogenic, Likely Pathogenic, or a Variant of Uncertain Significance (VUS)? A VUS means the lab isn’t sure if the variant affects health at all.
Your Disease Course and Prognosis
One of the most common questions after a genetic diagnosis is: “Will my ALS be faster or slower because of this gene?”
Current medical research indicates that the course of NEK1-associated ALS generally mirrors that of sporadic ALS (ALS with no known genetic cause) [5]. There is no evidence currently that having a NEK1 variant automatically means a more aggressive or faster-progressing disease [12], though current data do not establish a distinct prognosis compared to sporadic ALS.
Your prognosis depends much more on individual clinical factors than on the gene itself. Your doctors will look at:
- Site of onset: Whether symptoms first started in your limbs (arms/legs) or the bulbar region (muscles used for speaking and swallowing) [13].
- Progression rate: How your symptoms change over months, often measured by a tool called the ALSFRS-R (ALS Functional Rating Scale-Revised).
- Respiratory function: How well your breathing muscles are working [14].
Managing Your Care
Because the clinical course of ALS24 is similar to other forms of ALS, your care will focus on the same gold-standard treatments. Research shows that being treated by a multidisciplinary care team—which includes neurologists, physical therapists, respiratory therapists, and nutritionists—significantly improves survival and quality of life [15][16].
Additionally, having a confirmed genetic variant can sometimes open doors to specialized clinical trials [17]. Researchers are currently looking at ways to stabilize the cellular structures that NEK1 usually protects, which may lead to new treatments in the future [4].
Genetic Counseling and Family
Finding a NEK1 variant may raise concerns about your biological relatives. Because of the incomplete penetrance mentioned above, the risk to family members is often lower than it would be for other highly penetrant genetic forms of ALS [18], but this risk is highly variant-specific.
Professional genetic counseling is recommended for anyone with a genetic finding in ALS [7]. A counselor can help explain the specific “weight” of your variant, discuss the pros and cons of testing for your relatives, and help you communicate this information to your family in a way that is clear and supportive [11].
Common questions in this guide
What does ALS24 mean, and how is it connected to NEK1?
Does carrying a NEK1 variant mean I will develop ALS?
Does NEK1-associated ALS progress faster than other forms of ALS?
How can I understand my NEK1 genetic test report?
Will a NEK1 result change my ALS treatment?
Should my relatives have NEK1 genetic testing?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on amyotrophic lateral sclerosis, susceptibility to, 24.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific NEK1 variant, am I considered to have a disease-associated variant or a risk allele?
- 2.Does having this genetic finding change any of your recommendations for my current treatment plan or multidisciplinary care?
- 3.Are there specific clinical trials currently recruiting for people with NEK1-associated ALS (ALS24)?
- 4.How should I talk to my family members about this result, and would they benefit from meeting with a genetic counselor?
- 5.Is my disease progression following the typical pattern you see in people with non-genetic (sporadic) ALS?
References
References (18)
- 1
NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.
Kenna KP, van Doormaal PT, Dekker AM, et al.
Nature genetics 2016; (48(9)):1037-42 doi:10.1038/ng.3626.
PMID: 27455347 - 2
A rare missense variant impacting NEK1 kinase function is associated with ALS.
Brenner D, Ponomarenko A, Petrut I, et al.
Acta neuropathologica communications 2026; (14(1)).
PMID: 42351313 - 3
NEK1 loss-of-function mutation induces DNA damage accumulation in ALS patient-derived motoneurons.
Higelin J, Catanese A, Semelink-Sedlacek LL, et al.
Stem cell research 2018; (30()):150-162 doi:10.1016/j.scr.2018.06.005.
PMID: 29929116 - 4
Loss of function of the ALS-associated NEK1 kinase disrupts microtubule homeostasis and nuclear import.
Mann JR, McKenna ED, Mawrie D, et al.
Science advances 2023; (9(33)):eadi5548 doi:10.1126/sciadv.adi5548.
PMID: 37585529 - 5
ALS-associated C21ORF2 variant disrupts DNA damage repair, mitochondrial metabolism, neuronal excitability and NEK1 levels in human motor neurons.
Zelina P, de Ruiter AA, Kolsteeg C, et al.
Acta neuropathologica communications 2024; (12(1)):144 doi:10.1186/s40478-024-01852-6.
PMID: 39227882 - 6
NEK1 mutations and the risk of amyotrophic lateral sclerosis (ALS): a meta-analysis.
Yao L, He X, Cui B, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(4)):1277-1285 doi:10.1007/s10072-020-05037-6.
PMID: 33462636 - 7
Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis.
Volk AE, Weishaupt JH, Andersen PM, et al.
Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V 2018; (30(2)):252-258 doi:10.1007/s11825-018-0185-3.
PMID: 30220791 - 8
NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients.
Nguyen HP, Van Mossevelde S, Dillen L, et al.
Neurobiology of aging 2018; (61()):255.e1-255.e7 doi:10.1016/j.neurobiolaging.2017.08.021.
PMID: 28935222 - 9
Hand-onset weakness is a common feature of ALS patients with a NEK1 loss-of-function variant.
Tsai YS, Lin KP, Jih KY, et al.
Annals of clinical and translational neurology 2020; (7(6)):965-971 doi:10.1002/acn3.51064.
PMID: 32462798 - 10
Exploring NEK1 genetic variability in Italian amyotrophic lateral sclerosis patients.
Pensato V, Peverelli S, Tiloca C, et al.
Journal of neurology 2025; (272(7)):469 doi:10.1007/s00415-025-13153-6.
PMID: 40536530 - 11
High-Throughput Genetic Testing in ALS: The Challenging Path of Variant Classification Considering the ACMG Guidelines.
Lattante S, Marangi G, Doronzio PN, et al.
Genes 2020; (11(10)) doi:10.3390/genes11101123.
PMID: 32987860 - 12
The epidemiology of amyotrophic lateral sclerosis.
Talbott EO, Malek AM, Lacomis D
Handbook of clinical neurology 2016; (138()):225-38.
PMID: 27637961 - 13
Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis).
Jawdat O, Statland JM, Barohn RJ, et al.
Neurologic clinics 2015; (33(4)):775-85.
PMID: 26515621 - 14
ALS: Management Problems.
Brent JR, Franz CK, Coleman JM, Ajroud-Driss S
Neurologic clinics 2020; (38(3)):565-575 doi:10.1016/j.ncl.2020.03.013.
PMID: 32703469 - 15
Pathogenesis of amyotrophic lateral sclerosis.
Morgan S, Orrell RW
British medical bulletin 2016; (119(1)):87-98 doi:10.1093/bmb/ldw026.
PMID: 27450455 - 16
Oropharyngeal Dysphagia as the Main Expression of Amyotrophic Lateral Sclerosis.
Rugaitienė M, Damulevičienė G, Lesauskaitė V, Ulozienė I
Medicina (Kaunas, Lithuania) 2022; (58(5)) doi:10.3390/medicina58050647.
PMID: 35630064 - 17
Diagnostic delay in amyotrophic lateral sclerosis.
Gwathmey KG, Corcia P, McDermott CJ, et al.
European journal of neurology 2023; (30(9)):2595-2601 doi:10.1111/ene.15874.
PMID: 37209406 - 18
Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians.
Roggenbuck J, Quick A, Kolb SJ
Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(3)):267-274 doi:10.1038/gim.2016.107.
PMID: 27537704
This page explains ALS24 and NEK1 genetic findings for informational purposes only and does not constitute medical advice. Your neurologist and genetic counselor should interpret your specific result and guide treatment, family testing, and clinical-trial decisions.